[HTML][HTML] Towards personalized therapy in pediatric acute lymphoblastic leukemia; RAS mutations and prednisolone resistance
IM Ariës, R van den Dungen, M Koudijs, E Cuppen… - Blood, 2014 - Elsevier
Abstract Background: The 5-year event-free survival of pediatric precursor-B acute
lymphoblastic leukemia (BCP-ALL) has currently reached 80-90%. Targeted drugs are …
lymphoblastic leukemia (BCP-ALL) has currently reached 80-90%. Targeted drugs are …
Towards Personalized Therapy in Pediatric Acute Lymphoblastic Leukemia; Ras Mutations and Prednisolone Resistance
IM Ariës, R van den Dungen, M Koudijs, E Cuppen… - 2014 - ashpublications.org
Abstract Background: The 5-year event-free survival of pediatric precursor-B acute
lymphoblastic leukemia (BCP-ALL) has currently reached 80-90%. Targeted drugs are …
lymphoblastic leukemia (BCP-ALL) has currently reached 80-90%. Targeted drugs are …
Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance
IM Ariës, RE van den Dungen, MJ Koudijs… - …, 2015 - pubmed.ncbi.nlm.nih.gov
Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and
prednisolone resistance Towards personalized therapy in pediatric acute lymphoblastic …
prednisolone resistance Towards personalized therapy in pediatric acute lymphoblastic …
[HTML][HTML] Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance
IM Ariës, RE van den Dungen, MJ Koudijs… - …, 2015 - ncbi.nlm.nih.gov
Optimization of treatment protocols and improved risk stratification have enhanced event-
free survival rates in pediatric precursor-B acute lymphoblastic leukemia (BCPALL) up to …
free survival rates in pediatric precursor-B acute lymphoblastic leukemia (BCPALL) up to …
[HTML][HTML] Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance
IM Ariës, RE van den Dungen, MJ Koudijs… - …, 2015 - haematologica.org
Bone marrow samples were collected from children with newly diagnosed ALL after written
consent as approved by the institutional review board. Mononuclear cells were isolated by …
consent as approved by the institutional review board. Mononuclear cells were isolated by …
[PDF][PDF] Towards personalized therapy in pediatric acute lymphoblastic leukemia; RAS mutations and prednisolone resistance
IM Ariës, RE van den Dungen, MJ Koudijs, E Cuppen… - 2014 - researchgate.net
Optimization of treatment protocols and improved risk stratification have enhanced event-‐
free survival rates in pediatric precursor-‐B acute lymphoblastic leukemia (BCP-‐ALL) up to …
free survival rates in pediatric precursor-‐B acute lymphoblastic leukemia (BCP-‐ALL) up to …
[引用][C] Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance
I Ariës, R van den Dungen, MJ Koudijs, E Cuppen… - Haematologica, 2015 - repub.eur.nl
RePub, Erasmus University Repository: Towards personalized therapy in pediatric acute
lymphoblastic leukemia: RAS mutations and prednisolone resistance university website …
lymphoblastic leukemia: RAS mutations and prednisolone resistance university website …
[引用][C] Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance
IM Ariës, RE van den Dungen, MJ Koudijs, E Cuppen… - Haematologica, 2015 - pure.knaw.nl
Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and
prednisolone resistance — Royal Netherlands Academy of Arts and Sciences (KNAW) Skip to …
prednisolone resistance — Royal Netherlands Academy of Arts and Sciences (KNAW) Skip to …
Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance.
IM Ariës, RE van den Dungen, MJ Koudijs… - …, 2014 - europepmc.org
Optimization of treatment protocols and improved risk stratification have enhanced event-
free survival rates in pediatric precursor-B acute lymphoblastic leukemia (BCPALL) up to …
free survival rates in pediatric precursor-B acute lymphoblastic leukemia (BCPALL) up to …
[HTML][HTML] Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance
IM Ariës, RE van den Dungen, MJ Koudijs… - …, 2015 - haematologica.org
Optimization of treatment protocols and improved risk stratification have enhanced event-
free survival rates in pediatric precursor-B acute lymphoblastic leukemia (BCP-ALL) up to …
free survival rates in pediatric precursor-B acute lymphoblastic leukemia (BCP-ALL) up to …